Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation

Vascular endothelial growth factor (VEGF) blockade has been validated clinically as a treatment for human cancers, yet virtually all patients eventually develop progressive disease during therapy. In order to dissect this phenomenon, we examined the effect of sustained VEGF blockade in a model of advanced pediatric cancer. Treatment of late-stage hepatoblastoma xenografts resulted in the initial collapse of the vasculature and significant tumor regression. However, during sustained treatment, vessels recovered, concurrent with a striking increase in tumor expression of perlecan, a heparan sulfate proteoglycan. Whereas VEGF mRNA was expressed at the periphery of surviving clusters of tumor cells, both secreted VEGF and perlecan accumulated circumferential to central vessels. Vascular expression of heparanase, VEGF receptor-2 ligand binding, and receptor activation were concurrently maintained despite circulating unbound VEGF Trap. Endothelial survival signaling via Akt persisted. These findings provide a novel mechanism for vascular survival during sustained VEGF blockade and indicate a role for extracellular matrix molecules that sequester and release biologically active VEGF. (Mol Cancer Res 2008;6(1):1–9)

[1]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[2]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[3]  R. Sanderson,et al.  Heparanase Degrades Syndecan-1 and Perlecan Heparan Sulfate , 2004, Journal of Biological Chemistry.

[4]  A. Scaloni,et al.  Fibromodulin Gene Transcription Is Induced by Ultraviolet Irradiation, and Its Regulation Is Impaired in Senescent Human Fibroblasts* , 2005, Journal of Biological Chemistry.

[5]  J. Couchman,et al.  Perlecan and Tumor Angiogenesis , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  Peter Vajkoczy,et al.  Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  R. Kalluri.  Basement membranes: structure, assembly and role in tumour angiogenesis , 2003, Nature reviews. Cancer.

[8]  R. Brekken,et al.  Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.

[9]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[10]  D. McDonald,et al.  Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. , 2003, The American journal of pathology.

[11]  Eugene S. Kim,et al.  TNP-470 promotes initial vascular sprouting in xenograft tumors. , 2004, Molecular cancer therapeutics.

[12]  D. McDonald,et al.  Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. , 2004, The American journal of pathology.

[13]  Eugene S. Kim,et al.  Topotecan is anti-angiogenic in experimental hepatoblastoma. , 2002, Journal of pediatric surgery.

[14]  Craig Freeman,et al.  A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer , 2005, Oncogene.

[15]  Eugene S. Kim,et al.  Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. , 2004, Molecular cancer research : MCR.

[16]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[17]  M. Nugent,et al.  Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. , 1998, The Journal of clinical investigation.

[18]  J. Thyberg,et al.  Increased Intimal Hyperplasia and Smooth Muscle Cell Proliferation in Transgenic Mice With Heparan Sulfate–Deficient Perlecan , 2004, Circulation research.

[19]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[20]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[21]  S. Al-Sarraj,et al.  The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours , 2002, Neuropathology and applied neurobiology.

[22]  N. Ortéga,et al.  Extracellular matrix‐bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Jianzhong Huang,et al.  Regression of established tumors and metastases by potent vascular endothelial growth factor blockade , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Eberhard,et al.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.

[25]  I. Vlodavsky,et al.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. , 2001, The Journal of clinical investigation.

[26]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Stallcup,et al.  NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[28]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[29]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[30]  M. Weiser-Evans,et al.  Perlecan-Induced Suppression of Smooth Muscle Cell Proliferation Is Mediated Through Increased Activity of the Tumor Suppressor PTEN , 2004, Circulation research.